NICE rejected Novartis' Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Merck & Co. has priced Keytruda at about $2,600 per vial in China, about a 50% discount compared to its U.S. tag.
Amgen osteoporosis drug Prolia is working to appeal to menopausal women with a new TV ad, but it's leaving behind its celebrity spokeswoman.
Clovis Oncology may have ditched development of cancer treatment rociletinib years ago, but the drug will cost the company more than $20 million.
Move over, Siri and Alexa: There’s a new voice in town. Meet Sophia, Novo Nordisk’s first chatbot built specifically for people with diabetes.
A California lawsuit alleges that AbbVie grew Humira sales through kickbacks and nurse "ambassadors" at the expense of patient safety.
At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.
AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
NICE said yes to Novartis’ Tafinlar and Mekinist in adjuvant melanoma, giving the company a head start over rival BMS.
After months of pretrial proceedings and four weeks at trial, Imerys chose to settle a mesothelioma case in California.